5-Amino-1MQ vs GLP-1 (7-37)

Inhibits NNMT enzyme, increasing SAM (S-adenosylmethionine) availability. Alters adipocyte gene expression to reduce fat cell size and may increase brown adipose tissue activity via epigenetic mechanisms.

5-Amino-1-methylquinolinium (5-amino-1MQ) is a non-peptide small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM) as a methyl donor; NNMT is overexpressed in adipose tissue and has been identified as a metabolic regulator linking one-carbon metabolism, cellular methylation capacity, and adipogenesis. NNMT inhibition by 5-amino-1MQ is proposed to increase intracellular SAM and polyamine availability, shifting the cellular methylation balance in adipocytes toward suppression of adipogenesis and promotion of thermogenic gene expression; preclinical studies have examined effects on adipose tissue energy expenditure, systemic metabolism, and gut microbiome composition in diet-induced obesity mouse models. The best available indexed evidence is a preclinical study in diet-induced obese mice demonstrating that NNMT inhibition combined with caloric restriction altered microbiome composition and metabolic parameters; no human pharmacokinetic, safety, or efficacy data for 5-amino-1MQ has been published in any PubMed-indexed journal. 5-Amino-1MQ is a non-peptide research compound with no FDA approval or regulatory approval in any jurisdiction; it is not a peptide in the pharmacological sense and carries no human evidence base; all interest derives from preclinical metabolic data that has not been translated to human investigation. 5-Amino-1MQ dosage: No human clinical trial has established a dosing protocol for 5-Amino-1MQ. Preclinical research in rodent models has investigated this NNMT inhibitor at varying concentrations to assess metabolic effects. 5-Amino-1MQ is a research compound with no approved human dosing guidelines for any indication. Research protocols have explored oral and injectable delivery routes.

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

GLP-1(7-37) is the native 30-amino-acid active form of glucagon-like peptide 1, an endogenous incretin hormone secreted by intestinal L-cells in response to nutrient ingestion, that acts at GLP-1 receptors throughout the body to stimulate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, reduce appetite, and protect beta-cell mass; it is the endogenous ligand underlying the pharmacology of the GLP-1 receptor agonist drug class. The GLP-1 receptor is expressed on pancreatic beta cells, hypothalamic appetite-regulating neurons, gastric enteric neurons, and cardiovascular tissue; GLP-1(7-37) activates cAMP/PKA signaling in beta cells to potentiate insulin release strictly during hyperglycemia, providing intrinsic hypoglycemia protection, and centrally reduces caloric intake through satiety signaling. A randomized controlled trial of continuous subcutaneous native GLP-1 infusion in patients with type 2 diabetes demonstrated significant reductions in plasma glucose and appetite, confirming receptor-mediated effects of the native peptide in humans; the peptide's very short plasma half-life of approximately 2 minutes due to rapid DPP-IV degradation makes continuous infusion the only practical administration route for the native form. Native GLP-1(7-37) has no FDA approval as a drug; FDA-approved GLP-1 receptor agonists — including semaglutide, liraglutide, dulaglutide, and tirzepatide — are chemically modified DPP-IV-resistant analogs developed to overcome the native peptide's pharmacokinetic limitations, and research-grade native GLP-1 is used exclusively as a tool compound in metabolic pharmacology studies.